Clinical Trials Logo

Breakthrough Pain clinical trials

View clinical trials related to Breakthrough Pain.

Filter by:

NCT ID: NCT00994760 Completed - Cancer Clinical Trials

Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years

GENISIS
Start date: September 2009
Phase: N/A
Study type: Observational

The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks. The fentanyl spray was applied into the nose by a metered-spray device. The study was to provide further data on pharmacoeconomic efficiency of intranasal fentanyl spray.

NCT ID: NCT00833040 Completed - Pain Clinical Trials

A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain

Start date: April 2009
Phase: Phase 2
Study type: Interventional

The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.

NCT ID: NCT00813488 Completed - Chronic Pain Clinical Trials

Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain

Start date: December 2008
Phase: Phase 3
Study type: Interventional

Evaluate the efficacy of treatment with the fentanyl buccal tablet (FBT) compared with immediate release oxycodone treatment in alleviating breakthrough pain (BTP) in opioid tolerant patients with chronic pain.

NCT ID: NCT00684632 Completed - Pain, Cancer Clinical Trials

A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients

Start date: March 2008
Phase: Phase 3
Study type: Interventional

This study is designed to determine whether KW-2246 is superior to placebo and not inferior to immediate-release morphine for the relief of breakthrough pain in cancer patients.

NCT ID: NCT00576173 Completed - Pain Clinical Trials

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Start date: December 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the analgesic effectiveness and safety of 37.5mg Tramadol hydrochloride/325mg Acetaminophen in the treatment of breakthrough pain in cancer patients.

NCT ID: NCT00496392 Completed - Pain Clinical Trials

Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)

Start date: January 2007
Phase: Phase 3
Study type: Interventional

Primary: • To compare the efficacy of nasal fentanyl (NF) to oral transmucosal fentanyl (Actiq®) (hereafter Actiq) in the management of breakthrough pain in cancer patients. Secondary: - To compare patients' general impression and preference of NF and Actiq - To explore the relationship between NF doses and dose of current opioid for breakthrough pain (BTP) and the relationship between dose of NF and of background opioid - To assess safety and tolerability of NF

NCT ID: NCT00463047 Completed - Chronic Pain Clinical Trials

Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain

Start date: July 2007
Phase: Phase 3
Study type: Interventional

Evaluate the efficacy of treatment with Fentanyl Buccal Tablets (FBT) compared with immediate release oxycodone in alleviating breakthrough pain in opioid tolerant patients with chronic pain.

NCT ID: NCT00402350 Completed - Breakthrough Pain Clinical Trials

Staccato Fentanyl Single and Multidose PK

Start date: April 2006
Phase: Phase 1
Study type: Interventional

The Phase I clinical trial in approximately 50 healthy volunteers will be conducted at a single clinical center in two stages. Stage 1 is an open-label, cross-over comparison of a single dose of Staccato Fentanyl and an equivalent dose of intravenous (IV) fentanyl. Stage 2 is a randomized, doubleblind, placebo-controlled dose escalation of Staccato Fentanyl, evaluating multiple doses of fentanyl. The three primary aims of the Phase I clinical trial are to evaluate the pharmacokinetics (PK) and absolute bioavailability for Fentanyl, compare the Staccato Fentanyl PK profile to the IV fentanyl PK profile, and examine the tolerability and safety of Staccato Fentanyl in a non-opioid-tolerant, healthy volunteer population.

NCT ID: NCT00362583 Completed - Cancer Clinical Trials

Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)

Start date: June 2006
Phase: Phase 3
Study type: Interventional

Primary objectives: - To confirm the efficacy of intranasal fentanyl titrated to doses 50, 100 or 200 µg for treatment of breakthrough pain (BTP) in cancer patients - To establish long-term safety of treatment with intranasal fentanyl Secondary objectives: - To explore the relationship between dose of background opioid treatment and titrated fentanyl dose

NCT ID: NCT00345735 Completed - Pain Clinical Trials

Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)

Start date: May 2006
Phase: Phase 2
Study type: Interventional

Primary Objective: To demonstrate the efficacy of intranasal fentanyl in the treatment of breakthrough pain (BTP) in cancer patients. Secondary Objective: To explore the relationship between the response to the fentanyl dose and the stable background pain opioid dose.